Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ruðer Boškovic Institute has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is assigned to 1 distinct examiner, Amanda Lynn Chi. The prosecution is taking place within 1 distinct art unit. Amanda Lynn Chi is the busiest examiner, overseeing 1 busiest examiner pending action. Since there is only 1 pending office action, this examiner is the sole official responsible for the current portfolio.
Practitioners should focus on the specific requirements of this 1 distinct examiner within the Biotechnology & Pharmaceuticals field, as the entire active prosecution is concentrated in this single art unit. The 1 pending office action requires a targeted response that addresses the rejections of Amanda Lynn Chi directly. Because the portfolio is limited to 1 distinct art unit, the practitioner can expect a consistent application of examination standards. This 1 busiest examiner pending action is the only active case, which simplifies the management of the Biotechnology & Pharmaceuticals portfolio. A successful resolution with the 1 distinct examiner would result in the allowance of the company's currently pending matter. The legal team should prioritize the examiner interview to clarify any technical issues raised in the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHI, AMANDA LYNN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847221 | INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHI, AMANDA LYNN | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847221 | INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHI, AMANDA LYNN | 1613 | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRuðer Boškovic Institute has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amanda Lynn Chi has the most, with 1 of Ruðer Boškovic Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
